BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 19072516)

  • 1. Association of human papillomavirus with vulvar and vaginal intraepithelial disease: opportunities for prevention.
    Pearson JM; Feltman RS; Twiggs LB
    Womens Health (Lond); 2008 Mar; 4(2):143-50. PubMed ID: 19072516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
    Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
    Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors.
    Smith JS; Backes DM; Hoots BE; Kurman RJ; Pimenta JM
    Obstet Gynecol; 2009 Apr; 113(4):917-924. PubMed ID: 19305339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
    Nygård M; Hansen BT; Dillner J; Munk C; Oddsson K; Tryggvadottir L; Hortlund M; Liaw KL; Dasbach EJ; Kjær SK
    PLoS One; 2014; 9(2):e88323. PubMed ID: 24505474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    ; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
    BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data.
    Joura EA; Garland SM; Paavonen J; Ferris DG; Perez G; Ault KA; Huh WK; Sings HL; James MK; Haupt RM;
    BMJ; 2012 Mar; 344():e1401. PubMed ID: 22454089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles.
    Capri S; Gasparini R; Panatto D; Demarteau N
    Gynecol Oncol; 2011 Jun; 121(3):514-21. PubMed ID: 21334734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccine.
    Luxembourg A; Kjaer SK; Nygard M; Ellison MC; Group T; Marshall JB; Radley D; Saah A
    Contemp Clin Trials; 2017 Jan; 52():54-61. PubMed ID: 27777126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human Papillomavirus Genotypes From Vaginal and Vulvar Intraepithelial Neoplasia in Females 15-26 Years of Age.
    Garland SM; Joura EA; Ault KA; Bosch FX; Brown DR; Castellsagué X; Ferenczy A; Ferris DG; Giuliano AR; Hernandez-Avila M; Huh WK; Iversen OE; Kjaer SK; Kurman RJ; Luna J; Monsonego J; Muñoz N; Paavonen J; Pitisuttihum P; Ronnett BM; Steben M; Stoler MH; Wheeler CM; Wiley DJ; Perez G; Saah AJ; Luxembourg A; Li S; DiNubile MJ; Wagner M; Velicer C
    Obstet Gynecol; 2018 Aug; 132(2):261-270. PubMed ID: 29995724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention.
    Forcier M; Musacchio N
    Dermatol Ther; 2010; 23(5):458-76. PubMed ID: 20868401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Few More Reasons to Vaccinate Against Human Papillomavirus: The Vulva and Vagina.
    Feldman S
    Obstet Gynecol; 2018 Aug; 132(2):259-260. PubMed ID: 29995721
    [No Abstract]   [Full Text] [Related]  

  • 13. [HPV vaccination in Germany Low vaccination rates endanger prevention goals].
    MMW Fortschr Med; 2009 Dec; 151(51-52):44-5. PubMed ID: 20088323
    [No Abstract]   [Full Text] [Related]  

  • 14. Cancers attributable to human papillomavirus infection.
    Grulich AE; Jin F; Conway EL; Stein AN; Hocking J
    Sex Health; 2010 Sep; 7(3):244-52. PubMed ID: 20719211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer.
    Hampl M; Sarajuuri H; Wentzensen N; Bender HG; Kueppers V
    Obstet Gynecol; 2006 Dec; 108(6):1361-8. PubMed ID: 17138767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New quadrivalent HPV vaccine developments.
    Tovar JM; Bazaldua OV
    Postgrad Med; 2008 Nov; 120(4):14-6. PubMed ID: 19020361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [AN HPV-ASSOCIATED DISEASES AND CERVICAL CANCER AND PROPHYLACTIC HUMAN PAPILLOMAVIRUS (HPV) VACCINES].
    Malinova M
    Akush Ginekol (Sofiia); 2015; 54 Suppl 1():25-31. PubMed ID: 26137767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection and Type-Distribution of Human Papillomavirus in Vulva and Vaginal Abnormal Cytology Lesions and Cancer Tissues from Thai Women.
    Ngamkham J; Boonmark K; Phansri T
    Asian Pac J Cancer Prev; 2016; 17(3):1129-34. PubMed ID: 27039737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
    Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
    Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States.
    Insinga RP; Liaw KL; Johnson LG; Madeleine MM
    Cancer Epidemiol Biomarkers Prev; 2008 Jul; 17(7):1611-22. PubMed ID: 18628412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.